Analysis
Aspen Neuroscience, Inc. filed an amended S-1 to list on the Nasdaq Global Select Market under ticker "ASPE," with its offering contingent on that listing approval, according to the filing with the SEC. The amendment leaves the share count and price range blank, pending finalization closer to pricing; underwriters include Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel and Oppenheimer.
A Parkinson's cell therapy built from a patient's own cells
The San Diego-area biotech, incorporated in Delaware in 2018 and built on research from Scripps Research Institute's Jeanne F. Loring, is developing autologous iPSC-derived cell therapies -- treatments grown from a patient's own reprogrammed stem cells rather than a universal donor line. Its lead candidate, sasineprocel, targets Parkinson's disease and is currently in the ASPIRO Phase 1/2a trial, with the company planning a Phase 3 trial next; a second, preclinical program targets pediatric leukodystrophies. CEO Damien McDevitt and Executive Chairman Faheem Hasnain lead a company that has raised about $347 million since inception from ARCH Venture Partners, OrbiMed, Frazier Life Sciences, Medical Excellence Capital and Kite, a Gilead company, with additional support from the California Institute for Regenerative Medicine.
“Loring, is developing autologous iPSC-derived cell therapies -- treatments grown from a patient's own reprogrammed stem cells rather than a universal donor line.”
The company has no approved products and no revenue. As of or for the periods shown, its prospectus discloses:
- Net loss, 2025 -- $62.1M
- Net loss, H1 2026 -- $36.5M
- Cash on hand, June 2026 -- $72.4M
- Accumulated deficit -- $264.9M
Those figures carry the standard going-concern language common to clinical-stage biotech prospectuses. Net proceeds from the IPO, combined with existing cash, are earmarked for continuing sasineprocel's clinical development, including the Phase 3 trial, rather than near-term commercialization.
Autologous cell therapy -- using a patient's own cells -- sidesteps the immune-rejection risk that comes with donor-derived treatments, but it makes manufacturing dramatically harder: each dose has to be custom-made per patient rather than produced at scale from a single cell bank. That manufacturing complexity is the central bear case for the category broadly, not specific to Aspen, and it's the reason the company's roughly $347 million in prior venture funding has gone almost entirely into getting one candidate through early-stage trials rather than building commercial infrastructure.
